ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of direct lytic
agents (DLAs), including lysins and amurin peptides, as new
modalities for the treatment of life-threatening,
antibiotic-resistant infections, today announced that the Company
has been selected to give a Late Breaker oral presentation on the
reduction in health resource utilization among
methicillin-resistant Staphylococcus aureus (MRSA) patients treated
with exebacase in the recently completed Phase 2 study of exebacase
at ID Week 2019, October 2-6, in Washington, DC. The company will
also present the results of antimicrobial susceptibility testing of
Staph aureus isolates from the Phase 2 clinical study, as well as
the results of several preclinical efficacy studies, which further
advance the understanding of activity of exebacase against biofilms
and in infective endocarditis.
The oral presentation will be given by Cara
Cassino, MD, ContraFect’s Chief Medical Officer and Executive Vice
President of Research & Development, who will discuss the
reductions in hospital length of stay and 30-day hospital
readmission rates among U.S. patients with MRSA bacteremia
including endocarditis who were treated with exebacase, compared to
those who received antibiotics alone in the Phase 2 trial of
exebacase. The Company will also present data on the activity of
exebacase against Staph aureus isolates from patients enrolled in
the Phase 2 trial. Additionally, the Company will present data on
the impact of dosing strategies in administering exebacase with
daptomycin in the rabbit model of infective endocarditis, the
activity of exebacase against biofilms formed on orthopedic
Kirschner wires and the exebacase pharmacokinetic/pharmacodynamic
(PK/PD) relationship in pre-clinical models.
Presentation Details:
Oral Presentation
Title: Exebacase (EXE) Reduced
Length of Stay and 30-Day Readmission Rates for US Patients with
Methicillin Resistant Staphylococcus aureus (MRSA) Bacteremia
Including Endocarditis Compared to Standard of Care Antibiotics
(SoC) Alone in a Phase 2 Study Session
Title: Late Breaker Oral Abstracts 1Abstract
Number: 725443Room: 209 ABTime
and Date: Thursday, October 3, 2019, 2:05 p.m. – 2:15 p.m.
ET
Presentation
Title: Exebacase (Lysin CF-301)
Activity Against Staphylococcus aureus (S. aureus) Isolates from
Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)
Session Title: Novel Antimicrobials and
Approaches Against Resistant BugsAbstract Number:
711Room: Exhibit Hall BCTime and
Date: Thursday, October 3, 2019, 12:15 p.m. – 1:30 p.m.
ET
Presentation
Title: Activity of Exebacase
(CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA)
Biofilms on Orthopedic Kirschner Wires Session
Title: Novel Antimicrobials and Approaches Against
Resistant BugsAbstract Number:
712Room: Exhibit Hall BCTime and
Date: Thursday, October 3, 2019, 12:15 p.m. – 1:30 p.m.
ET
Presentation
Title: Impact of Dose-Administration
Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in
Addition to Daptomycin (DAP) in an Experimental Infective
Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus
aureus (MRSA) Session Title: Novel
Antimicrobials and Approaches Against Resistant
BugsAbstract Number: 671Room:
Exhibit Hall BCTime and Date: Thursday, October 3,
2019, 12:15 p.m. – 1:30 p.m. ET
Presentation Title: PK-PD
Relationship and PK Driver of Efficacy of the Novel Antibacterial
Lysin Exebacase (CF-301) in Pre-Clinical ModelsSession
Title: PK/PD and Susceptibility
TestingAbstract Number: 1550Room:
Exhibit Hall BCTime and Date: Friday, October 4,
2019, 12:15 p.m. – 1:30 p.m. ET
The abstracts can be accessed through the IDWeek website.
Following the meeting, the presentation posters will be available
on the ContraFect website.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our platform of direct
lytic agents (DLAs), which include lysins and amurin peptides.
Lysins are a new class of DLAs which are recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics. Amurin peptides are new
class of DLAs which exhibit broad-spectrum activity against a wide
range of antibiotic-resistant Gram-negative pathogens, including
Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii,
and Enterobacter species. We believe that the properties of our
lysins and amurin peptides will make them suitable for targeting
antibiotic-resistant organisms, such as methicillin-resistant Staph
aureus (MRSA) and P. aeruginosa, which can cause serious infections
such as bacteremia, pneumonia and osteomyelitis. We have completed
a Phase 2 clinical trial for the treatment of Staph aureus
bacteremia, including endocarditis, with our lead lysin candidate,
exebacase (CF-301), which is the first lysin to enter clinical
studies in the U.S.
Follow ContraFect on Twitter @ContraFectCorp and
LinkedIn.
About Exebacase (CF-301):
Exebacase (CF-301) is a recombinantly-produced
lysin (cell wall hydrolase enzyme) with potent bactericidal
activity against Staph aureus, a major cause of blood stream
infections (BSIs) also known as bacteremia. It has a novel, rapid,
and specific mechanism of bactericidal action against Staph aureus.
By targeting a conserved region of the cell wall that is vital to
bacteria, resistance is less likely to develop to exebacase. We
have completed a Phase 2 superiority design clinical study with
exebacase which evaluated its safety, tolerability, efficacy and PK
when used in addition to standard-of-care (SOC) antibiotics for the
treatment of Staph aureus bacteremia, including endocarditis, in
adult patients. In a pre-specified analysis of MRSA-infected
patients, the clinical responder rate at day 14 in patients treated
with exebacase was 42.8% higher than the clinical responder rate in
patients treated with SOC antibiotics alone (74.1% for patients
treated with exebacase compared to 31.3% for patients treated with
SOC antibiotics alone (p=0.010)). Additionally, among US MRSA
patients discharged alive from the hospital, the median length of
stay was reduced by four days and the 30-day all cause readmission
rate was reduced to 16.0% from 30.8% in patients treated with
exebacase. We believe exebacase has the potential to be a
first-in-class treatment for Staph aureus bacteremia.
Exebacase was licensed from The Rockefeller University and is being
developed at ContraFect.
Forward-Looking Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding the planned
presentations, the Company’s ability to discover and develop DLAs
as new modalities for the treatment of life-threatening,
antibiotic-resistant infections, the Company’s ability to
address life threatening infections using its therapeutic product
candidates from its DLA platform, whether lysins are a new class of
DLAs which are recombinantly produced, antimicrobial proteins with
a novel mechanism of action associated with the rapid killing of
target bacteria, eradication of biofilms and synergy with
conventional antibiotics, whether amurins exhibit broad-spectrum
activity against a wide range of antibiotic-resistant Gram-negative
pathogens, whether the properties of the Company’s lysins and
amurins will make them suitable for targeting antibiotic-resistant
organisms, such as Staph aureus and P. aeruginosa, the potential
for exebacase to be a first-in-class treatment for Staph aureus
bacteremia, statements made regarding exebacase and Phase 2 study
results. Forward-looking statements are statements that are not
historical facts, nor assurances of future performance. Instead,
they are based on ContraFect’s current beliefs, expectations and
assumptions regarding the future of its business, future plans,
strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements
relate to the future, they are subject to inherent risks,
uncertainties and changes in circumstances that are difficult to
predict and many of which are beyond ContraFect’s control,
including those detailed under the caption “Risk Factors” in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024